Current Hematologic Malignancy Reports最新文献_第8页

Bispecific Antibodies for the Treatment of Multiple Myeloma. 治疗多发性骨髓瘤的双特异性抗体。

IF 2.7 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-12-01 Epub Date: 2022-08-27 DOI: 10.1007/s11899-022-00675-3

Scott R Goldsmith, Shawn Streeter, Fahrettin Covut

{"title":"Bispecific Antibodies for the Treatment of Multiple Myeloma.","authors":"Scott R Goldsmith, Shawn Streeter, Fahrettin Covut","doi":"10.1007/s11899-022-00675-3","DOIUrl":"10.1007/s11899-022-00675-3","url":null,"abstract":"Purpose of review: Advances in multiple myeloma therapies have greatly improved outcomes for patients living with the disease, although to date there is yet to be a cure. Cellular and immunotherapies, approved or in development, offer the promise of significantly advancing toward that possibility. The aim of this review is to provide a synopsis and commentary on the current and future states of bispecific agents aimed at harnessing the antineoplastic potential of T-cells in treating and eradicating myeloma.Recent findings: Numerous bispecific agents are in clinical development with some on the precipice of regulatory approval. While BCMA remains the principal target, some agents are directed at novel targets such as GPRC5D and FcRH5. The constructs vary in design and pharmacokinetics which has dosing and administration implications. The toxicity profiles of these agents generally reflect that of other immune therapies, including cytokine release syndrome and rarely neurotoxicity, although immunosuppression has also led to elevated infection risks. However, the toxicities are generally manageable and offset by unprecedented efficacy seen in such heavily pretreated cohorts. Bispecific agents are poised to significantly alter the treatment paradigms for myeloma. They provide a convenient \"off-the-shelf\" platform with often deep and durable responses. Toxicities are often limited in duration and severity. In the early-phase trials, many patients have been able to remain on treatment for extended periods, even among those with high-risk features. Upcoming trials are likely to explore earlier implementation of these agents in order to offer this therapeutic opportunity to broader cohorts.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 6","pages":"286-297"},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10668759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions. 对第二代 TKIs 耐药的 CML：机制、下一步和新方向。

IF 2.7 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-12-01 Epub Date: 2022-10-20 DOI: 10.1007/s11899-022-00683-3

Emilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia

{"title":"CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions.","authors":"Emilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia","doi":"10.1007/s11899-022-00683-3","DOIUrl":"10.1007/s11899-022-00683-3","url":null,"abstract":"Purpose of review: The clinical scenario for chronic myeloid leukemia patients rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs). Second-generation TKIs as frontline treatment increased the rate of deep molecular responses without increasing the rate of overall survival. About 20% of patients experience resistance to these agents, needing alternative treatments. Here, we reviewed the possible mechanisms of resistance, available treatment, and new drugs developed to counteract and overcome resistance.Recent findings: Results of novel TKIs have been recently reported, especially for the setting of T315I mutated patients, such as olverembatinib and asciminib, or for patients who developed resistance due to other mutations, such as vodobatinib. Most of new TKIs are selected among compounds tested selective on ABL, therefore without possible off-target effects in the long term. New potential treatments are on the horizon in the field of CML, able to rescue patients treated firstly with one or more second-generation TKIs. Results of ongoing trials and real-world evidence dataset will help us to identify the appropriate timing of intervention and to select appropriate candidate to these drugs.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 6","pages":"198-205"},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10621385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms. DDX41的种系和体细胞缺陷及其对髓系肿瘤的影响。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-10-01 DOI: 10.1007/s11899-022-00667-3

Talha Badar, Timothy Chlon

{"title":"Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.","authors":"Talha Badar, Timothy Chlon","doi":"10.1007/s11899-022-00667-3","DOIUrl":"https://doi.org/10.1007/s11899-022-00667-3","url":null,"abstract":"Purpose of review: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.Recent findings: DDX41 encodes a DEAD-box helicase protein that is considered essential for cell growth and viability. High incidence of myeloid malignancies and other cancers in patients bearing DDX41m suggests that defects in DDX41 lead to loss of a tumor suppressor function, likely related to activities in RNA splicing and processing pathways. Seventy percent of cancer cases with DDX41m are associated with MDS/AML alone. More than 65% of familial cases harbor heterozygous germline frameshift mutations, of which p.D140Gfs*2 is the most common. A somatic DDX41m of the second allele is acquired in 70% of cases, leading to hematological malignancy. Myeloid neoplasms with DDX41m are typically characterized by long latency, high-risk disease at presentation with normal cytogenetics and without any additional molecular markers. Recent reports suggests that a subgroup of these patients have an indolent clinical course and have a better long-term survival compared to favorable or intermediate risk AML. Distinct clinical/pathologic features and favorable outcomes in MDS/AML highlight the need for standardized classification and gene specific guidelines that could assist in management decisions in patients with DDX41m.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 5","pages":"113-120"},"PeriodicalIF":2.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324161/pdf/nihms-1906846.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10133935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies 骨髓和其他造血系统恶性肿瘤的种系CHEK2和ATM变体

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-06-08 DOI: 10.1007/s11899-022-00663-7

Ryan J. Stubbins, S. Korotev, L. Godley

引用次数: 15

Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk DNA甲基化和组蛋白修饰与相关癌症风险的种系异常

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-06-02 DOI: 10.1007/s11899-022-00665-5

Jenna A. Fernandez, M. Patnaik

引用次数: 0

MRD in ALL: Optimization and Innovations ALL中的MRD：优化与创新

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-05-26 DOI: 10.1007/s11899-022-00664-6

E. Pierce, B. Mautner, J. Mort, Anastassia Blewett, A. Morris, M. Keng, F. El Chaer

引用次数: 3

Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders 端粒生物学障碍背景下的克隆性造血和骨髓瘤

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-05-07 DOI: 10.1007/s11899-022-00662-8

A. Ferrer, A. Mangaonkar, M. Patnaik

引用次数: 11

Targeting Apoptosis in ALL ALL靶向细胞凋亡

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-04-01 DOI: 10.1007/s11899-022-00661-9

Wesley M. Smith, Daniel R. Reed

引用次数: 0

Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia. 儿童、青少年和青年急性淋巴细胞白血病的长期护理面临的挑战。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2021-11-04 DOI: 10.1007/s11899-021-00657-x

Michael G Douvas, Lara L Riegler

{"title":"Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia.","authors":"Michael G Douvas, Lara L Riegler","doi":"10.1007/s11899-021-00657-x","DOIUrl":"https://doi.org/10.1007/s11899-021-00657-x","url":null,"abstract":"Purpose of review: To discuss the long-term view of treating and following pediatric, adolescent, and young adult patients with acute lymphoblastic leukemia (ALL) - with review of what can be done to prevent, monitor for, and treat complications of therapy.Recent findings: Pediatric, adolescent, and young adult oncology patients, including those with ALL, are living longer with higher overall survival rates as treatments and supportive care for these patients continue to improve. These patients are burdened by the risk of significant health and quality of life consequences as a result of their treatment.. For these patients, the late effects of treatment can be life-threatening, such as secondary cancers or cardiotoxicity, or life-altering with respect to quality of life. The goal of this paper is to review the current literature, research, and surveillance guidelines regarding the late effects of ALL therapy, to outline what can be done to mitigate the toxic effects of oncology treatment, and to extend life expectancy and improve quality of life for our patients. We review risk factors and interventions available to prevent and treat cardiovascular disease, secondary malignancies, endocrine complications (obesity, osteoporosis, infertility, and premature menopause), cognitive effects, and effects on functioning and mortality.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"15-24"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39590768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myeloproliferative Neoplasms with Monocytosis. 骨髓增生性肿瘤伴单核细胞增多症。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2021-11-13 DOI: 10.1007/s11899-021-00660-2

Erika Morsia, Naseema Gangat

{"title":"Myeloproliferative Neoplasms with Monocytosis.","authors":"Erika Morsia, Naseema Gangat","doi":"10.1007/s11899-021-00660-2","DOIUrl":"https://doi.org/10.1007/s11899-021-00660-2","url":null,"abstract":"Purpose of review: Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) that share driver mutations (JAK2/CALR/MPL) resulting in constitutive activation of JAK/STAT and other signaling pathways. Patients with MPN have shortened survival and an inherent risk for leukemic evolution. Prognostically relevant clinical and genetic parameters have been incorporated into mutation-enhanced scoring systems (MIPSS70-plus version 2.0, MIPSS-ET/PV). In the current review, we describe clinical and pathological features along with prognostic significance of MPN with monocytosis.Recent findings: Monocytosis, defined by an absolute monocyte count (AMC) ≥ 1 × 10 9/L, is a typical manifestation of chronic myelomonocytic leukemia (CMML) but is also associated with 21% and 17% of PV and PMF patients, respectively. Recent studies on the subject have reported that MPN patients with monocytosis are older and present with concomitant leukocytosis. In regard to PV, patients with monocytosis harbor unfavorable cytogenetic abnormalities including +8, 7/7q, i(17q), 5/5q-,12p-, inv(3), or 11q23 rearrangement and SRSF2 mutations, whereas PMF patients with monocytosis had significant thrombocytopenia, higher circulating blasts, higher symptom burden, and ASXL1 mutations. Moreover, presence of monocytosis predicted inferior survival in both PV and PMF. Monocytosis in MPN is associated with a distinct clinical and genetic profile and may serve as a marker of aggressive disease biology.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"46-51"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39620135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2